Antibody-based immunotherapies for Parkinsonian syndromes  

作　　者：Lars Tonges Maria Angela Samis Zella 

机构地区：[1]Department of Neurology,St. Josef-Hospital,Ruhr-University Bochum,Bochum,Germany [2]Neurodegeneration Research,Protein Research Unit Ruhr (PURE),Ruhr University Bochum,Bochum,Germany [3]Department of Neurology,St. Josef-Hospital,Katholische Kliniken Ruhrhalbinsel,Contilia Gruppe,Essen,Germany

出　　处：《Neural Regeneration Research》2019年第11期1903-1904,共2页中国神经再生研究（英文版）

摘　　要：What is the rationale for immunotherapies in Parkinsonian syndromes (PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major pathological hallmark of all PS consists of a non-physiological detrimental accumulation of protein aggregates which appear intracellularly in neurons and glial cells but also in the extracellular space (Wong and Krainc, 2017). Depending on the pathogenic protein, PS can be divided into synucleinopathies, characterized by aggregation of the protein alpha-Synuclein (aSyn), and tauopathies, characterized by aggregation of the protein Tau (Levin et al., 2016;Poewe et al., 2017). Clinical syndromes of synucleinopathies include Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies, and tauopathies include progressive supranuclear palsy (PSP) and corticobasal degeneration.

关 键 词：Parkinsonian SYNDROMES Parkinson’s disease(PD) multiple system atrophy(MSA) 

分 类 号：R[医药卫生]